Compare
Jazz Pharmaceuticals plc vs Elanco Animal Health Inc vs BeOne Medicines Ltd. vs Amneal Pharmaceuticals, Inc.
| Latest fiscal year | Jazz Pharmaceuticals plc JAZZ | Elanco Animal Health Inc ELAN | BeOne Medicines Ltd. ONC | Amneal Pharmaceuticals, Inc. AMRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.27B | $4.71B | $5.34B | $3.02B |
| Revenue growth (YoY) | +4.9% | +6.2% | +40.2% | +8.0% |
| Gross margin | n/a | 55.0% | 87.5% | 36.9% |
| Operating margin | -10.1% | n/a | 8.4% | 13.1% |
| Net margin | -8.3% | -4.9% | 5.4% | 2.4% |
| Net income | -$356.15M | -$232.00M | $286.93M | $72.06M |
| EPS (Diluted) | -$5.84 | -$0.47 | $0.19 | $0.22 |
| Operating cash flow | $1.36B | $560.00M | $1.13B | $339.99M |
| Free cash flow | $1.30B | $284.00M | $941.74M | $269.93M |
| Cash & equivalents | $1.39B | $545.00M | $4.55B | $282.03M |
| Total assets | $11.66B | $13.36B | $8.19B | $3.68B |
| Total liabilities | n/a | $6.81B | $3.83B | n/a |
| Shareholders' equity | $4.32B | $6.55B | $4.36B | -$70.79M |
| Return on year-end equity | -8.2% | -3.5% | 6.6% | n/a |
| Shares outstanding | 61.44M | 496.98M | 1.44B | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Jazz Pharmaceuticals plc | Elanco Animal Health Inc | BeOne Medicines Ltd. | Amneal Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $4.27B Ended 2025-12-31 | $4.71B Ended 2025-12-31 | $5.34B Ended 2025-12-31 | $3.02B Ended 2025-12-31 |
| 1 year earlier | $4.07B Ended 2024-12-31 | $4.44B Ended 2024-12-31 | $3.81B Ended 2024-12-31 | $2.79B Ended 2024-12-31 |
| 2 years earlier | $3.83B Ended 2023-12-31 | $4.42B Ended 2023-12-31 | $2.46B Ended 2023-12-31 | $2.39B Ended 2023-12-31 |
| 3 years earlier | $3.66B Ended 2022-12-31 | $4.41B Ended 2022-12-31 | $1.42B Ended 2022-12-31 | $2.21B Ended 2022-12-31 |
| 4 years earlier | $3.09B Ended 2021-12-31 | $4.76B Ended 2021-12-31 | $1.18B Ended 2021-12-31 | $2.09B Ended 2021-12-31 |